Business
Azitra is developing precision dermatology therapies using engineered proteins and topical live biotherapeutic products.
Azitra had no revenue, wider losses, deeper cash burn, lower equity, and an Altman-Z distress reading.
The read at a glance✓ Audited against SEC data
- Business mix — Precision dermatology platformNote
- Revenue — Revenue fell to zeroWatch
- Losses — Net loss widened to $11.0MWatch
- Cash — Free cash flow worsened to -$11.2MWatch
- Balance sheet — Equity fell 33.3%Watch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distress; other screens unavailableWatch
Latest filings
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-06-17
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Azitra, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.